CN104968685A - 异源二聚免疫球蛋白的纯化 - Google Patents

异源二聚免疫球蛋白的纯化 Download PDF

Info

Publication number
CN104968685A
CN104968685A CN201380061419.1A CN201380061419A CN104968685A CN 104968685 A CN104968685 A CN 104968685A CN 201380061419 A CN201380061419 A CN 201380061419A CN 104968685 A CN104968685 A CN 104968685A
Authority
CN
China
Prior art keywords
immunoglobulin
fragment
district
constant region
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061419.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦尼斯拉斯·布兰
法布里齐奥·康珀
罗曼·奥利耶
保罗·瓦斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of CN104968685A publication Critical patent/CN104968685A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380061419.1A 2012-09-25 2013-09-25 异源二聚免疫球蛋白的纯化 Pending CN104968685A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
US61/705,278 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Publications (1)

Publication Number Publication Date
CN104968685A true CN104968685A (zh) 2015-10-07

Family

ID=49237223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061419.1A Pending CN104968685A (zh) 2012-09-25 2013-09-25 异源二聚免疫球蛋白的纯化

Country Status (11)

Country Link
US (2) US20150239991A1 (US07714131-20100511-C00024.png)
EP (2) EP3401337A1 (US07714131-20100511-C00024.png)
JP (5) JP2015529236A (US07714131-20100511-C00024.png)
KR (1) KR20150076172A (US07714131-20100511-C00024.png)
CN (1) CN104968685A (US07714131-20100511-C00024.png)
AU (2) AU2013322710A1 (US07714131-20100511-C00024.png)
CA (2) CA3061557A1 (US07714131-20100511-C00024.png)
HK (1) HK1215950A1 (US07714131-20100511-C00024.png)
IL (2) IL237872B (US07714131-20100511-C00024.png)
IN (1) IN2015MN00139A (US07714131-20100511-C00024.png)
WO (1) WO2014049003A1 (US07714131-20100511-C00024.png)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071635A (zh) * 2016-05-02 2018-12-21 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109790215A (zh) * 2016-09-29 2019-05-21 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN112262154A (zh) * 2018-04-26 2021-01-22 利摩日大学 人类重链伪γ基因编码的新型IGG5类重组免疫球蛋白
US11129905B2 (en) 2015-10-25 2021-09-28 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
US11192960B2 (en) 2016-04-13 2021-12-07 Sanofi Trispecific and/or trivalent binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
US11932704B2 (en) 2016-04-13 2024-03-19 Sanofi Trispecific and/or trivalent binding proteins

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
IN2015MN00139A (US07714131-20100511-C00024.png) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
KR20160104636A (ko) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
JP7031810B2 (ja) 2016-11-18 2022-03-08 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
WO2019243626A1 (en) 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020136564A1 (en) 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
CA3163017A1 (en) * 2019-12-26 2021-07-01 Daehae SONG Method for purifying biologically active peptide by using protein a affinity chromatography
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024050493A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN102264759A (zh) * 2008-12-23 2011-11-30 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2445936A1 (en) * 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9150663B2 (en) * 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
EP2771364B1 (en) * 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
AU2012372484A1 (en) 2012-03-06 2014-08-21 Foss Analytical Ab Method, software and graphical user interface for forming a prediction model for chemometric analysis
DK2825559T3 (da) 2012-03-13 2019-06-03 Novimmune Sa Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
IN2015MN00139A (US07714131-20100511-C00024.png) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN102264759A (zh) * 2008-12-23 2011-11-30 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129905B2 (en) 2015-10-25 2021-09-28 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
TWI750139B (zh) * 2015-10-25 2021-12-21 法商賽諾菲公司 用於預防或治療ｈｉｖ感染之三特異性及/或三價結合蛋白
US11779651B2 (en) 2015-10-25 2023-10-10 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
US11192960B2 (en) 2016-04-13 2021-12-07 Sanofi Trispecific and/or trivalent binding proteins
TWI788286B (zh) * 2016-04-13 2023-01-01 法商賽諾菲公司 三特異性和/或三價結合蛋白
US11932704B2 (en) 2016-04-13 2024-03-19 Sanofi Trispecific and/or trivalent binding proteins
CN109071635A (zh) * 2016-05-02 2018-12-21 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109071635B (zh) * 2016-05-02 2023-09-01 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109790215A (zh) * 2016-09-29 2019-05-21 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN109790215B (zh) * 2016-09-29 2023-06-30 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN112262154A (zh) * 2018-04-26 2021-01-22 利摩日大学 人类重链伪γ基因编码的新型IGG5类重组免疫球蛋白
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
HK1215950A1 (zh) 2016-09-30
JP2019073512A (ja) 2019-05-16
JP6856610B2 (ja) 2021-04-07
WO2014049003A1 (en) 2014-04-03
IL237872B (en) 2019-09-26
IL269207B (en) 2022-02-01
JP2015529236A (ja) 2015-10-05
CA2886036A1 (en) 2014-04-03
AU2013322710A1 (en) 2015-04-16
AU2018204314B2 (en) 2020-05-14
EP2900696A1 (en) 2015-08-05
AU2013322710A2 (en) 2015-05-07
IN2015MN00139A (US07714131-20100511-C00024.png) 2015-10-16
US20200010568A1 (en) 2020-01-09
JP2018104444A (ja) 2018-07-05
US20150239991A1 (en) 2015-08-27
CA3061557A1 (en) 2014-04-03
EP3401337A1 (en) 2018-11-14
IL237872A0 (en) 2015-05-31
KR20150076172A (ko) 2015-07-06
IL269207A (en) 2019-11-28
JP2020105203A (ja) 2020-07-09
AU2018204314A1 (en) 2018-07-05
JP2022116326A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
AU2019257534B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
AU2017279804B2 (en) Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
US20220098326A1 (en) Method for generating avid-binding multispecific antibodies
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
IL301473A (en) EGFR binding complex and how it is created and used
KR20240049318A (ko) Fap/cd40 결합 분자 및 이의 의학적 용도
TW202409093A (zh) 融合蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215950

Country of ref document: HK